The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to methods, uses, a first MCM5 binding agent and/or a second MCM5 binding agents and kits for detecting the presence or absence of a cancer in a subject and/or diagnosing a subject with a cancer and/or monitoring a subject for recurrence of a cancer.

A reagent, test paper, a reagent kit, and a test paper kit for detecting a sulfhydryl compound, and a preparation method thereof are provided. The reagent is obtained by mixing a phosphotungstic acid (PTA) reagent, an acetate buffer, and a shield reagent in a specified ratio. The test paper is composed of porous water-absorbent paper and a dry detection reagent dispersed thereon. The reagent is based on principle innovation. When in use, the reagent is directly mixed with urine to be tested in a volume ratio of 2:1, a resulting mixture is allowed to stand for 10 min to 15 min, and then a result can be directly determined by naked eyes. The reagent overcomes the shortcoming of requiring a control sample to assist in the determination of a result in existing methods, and has the advantages of simple operation, safety and non-toxicity, and rapid detection.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention refers to an in vitro method for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.

The present invention relates to methods of prognosing and monitoring cancer using circulating cells and/or extracellular vesicles as indicators of the progression of plasma cell neoplasms in patients.

The invention relates to a method for examining a human or animal cell specimen, comprising the steps: a) providing at least one combinatorial cluster (CMP) which is characteristic of a disease, the CMP characterizing the colocalization and/or anticolocalization of multiple biological features in a voxel; b) determining N tags which are sufficient to determine CMP; c) bringing the cell specimen into contact with the N tags; d) measuring the cell specimen by means of flow cytometry to obtain flow cytometric data; and e) using the flow-cytometric data to check whether the CMP occurs in the cell. The invention further relates to a flow cytometer (10).

An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.